Ficlatuzumab
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF) . Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion[1].
Product Specifications
CAS Number
1174900-84-5
UNSPSC
12352203
Target
C-Met/HGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ficlatuzumab.html
Purity
99.21
Solubility
10 mM in DMSO
Smiles
[Ficlatuzumab]
Molecular Weight
(144.5 kDa)
References & Citations
[1]Kumar D, et al. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg. 2015 Dec;141 (12) :1133-9.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog